Most pancreatic cancers possess point mutations in the K-Ras oncogene. The majority of K-Ras point mutations result in K-Ras being constitutively activated leading to increased cell proliferation, growth, and inhibition of apoptotic pathways. Studies have suggested that small interfering RNA (siRNA) designed against mutated K-Ras (mK-Ras) may be a treatment option for pancreatic cancers. The aim of this study was to characterize the effects of mK-Ras siRNA on cell viability, proliferation, and metabolic activity in pancreatic cancer cell lines.
|Number of pages||1|
|Publication status||Published - 2013|
|Event||Western Regional Meeting of the American Federation for Medical Research - Carmel, United States|
Duration: 24 Jan 2013 → 26 Jan 2013
|Conference||Western Regional Meeting of the American Federation for Medical Research|
|Period||24/01/13 → 26/01/13|